Molecular mechanisms of MET tyrosine kinase during tumor progression and metastasis

Document Type : Review article

Authors

1 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

10.22038/mjms.2025.79037.4549

Abstract

Due to the side effects caused by common cancer treatments such as chemotherapy and radiotherapy, it is required to introduce the novel therapeutic options in cancer patients. In recent years, the molecular orientation of cancer treatment is considered as the most effective approach in personalized cancer medicine. The use of tyrosine kinase inhibitors can be a promising approach for cancer treatment. MET is a receptor tyrosine kinase that has a key role in inducing cell proliferation, angiogenesis, and cell migration, and tumor progression. MET deregulation is associated with poor prognosis and drug resistance in a wide range of cancers. Regarding the role of MET in many physiological and pathological processes, it can be considered as a therapeutic target in tumor cells. Small-molecule tyrosine kinase inhibitors (TKIs) such as crizotinib, capmatinib, and cabozantinib have reliable efficacy to improve progression-free survival in cancer patients by MET inhibition. Monoclonal antibodies also disrupt ligand-MET interactions to improve patient’s survival. However, resistance toward the MET inhibitors can be observed due to the various molecular mechanisms such as MET duplication and up regulation, mutation, and activation of parallel signaling pathways. PubMed, Google Scholar, Scopus, and Web of Science were used for data retrieval until 2024 using the “MET” and "cancer" keywords. This review has an important role to clarify the molecular biology of MET during tumor progression to introduce novel efficient therapeutic strategies to overcome resistance toward MET inhibitors among cancer patients.

Keywords

References

  1. Skobridis K, Kinigopoulou M, Theodorou V, Giannousi E, Russell A, Chauhan R, et al. Novel Imatinib Derivatives with Altered Specificity between Bcr–Abl and FMS, KIT, and PDGF Receptors. ChemMedChem. 2010;5(1):130-9.
  2. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nature Reviews Drug Discovery. 2007;6(2):115-20.
  3. Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes and environment : the official journal of the Japanese Environmental Mutagen Society. 2021;43(1):21.
  4. Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer cell international. 2021;21(1):213.
  5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-34.
  6. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-65.
  7. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Current opinion in cell biology. 2007;19(2):117-23.
  8. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annual review of biochemistry. 2000;69(1):373-98.
  9. Moghbeli M, Makhdoumi Y, Soltani Delgosha M, Aarabi A, Dadkhah E, Memar B, et al. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biological research. 2019;52(1):2.
  10. Maharati A, Zanguei AS, Khalili-Tanha G, Moghbeli M. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell communication and signaling : CCS. 2022;20(1):27.
  11. Yano S, Nakagawa T. The current state of molecularly targeted drugs targeting HGF/Met. Japanese journal of clinical oncology. 2014;44(1):9-12.
  12. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proceedings of the National Academy of Sciences. 2003;100(21):12039-44.
  13. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proceedings of the National Academy of Sciences. 2003;100(22):12654-9.
  14. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular cell. 2001;8(5):995-1004.
  15. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77(2):261-71.
  16. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 2009;63(2):169-79.
  17. Palka HL, Park M, Tonks NK. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. Journal of Biological Chemistry. 2003;278(8):5728-35.
  18. Sangwan V, Paliouras GN, Abella JV, Dubé N, Monast A, Tremblay ML, et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. Journal of Biological Chemistry. 2008;283(49):34374-83.
  19. Kobayashi T, Honke K, Miyazaki T, Matsumoto K, Nakamura T, Ishizuka I, et al. Hepatocyte growth factor specifically binds to sulfoglycolipids. Journal of Biological Chemistry. 1994;269(13):9817-21.
  20. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. The Journal of cell biology. 1993;123(1):223-35.
  21. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332-7.
  22. Furlan A, Kherrouche Z, Montagne R, Copin M-C, Tulasne D. Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer research. 2014;74(23):6737-44.
  23. Maina F, Casagranda F, Audero E, Simeone A, Comoglio PM, Klein R, et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell. 1996;87(3):531-42.
  24. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. The Journal of cell biology. 2000;149(7):1419-32.
  25. Fixman ED, Naujokas MA, Rodrigues GA, Moran MF, Park M. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene. 1995;10(2):237-49.
  26. Xiao G-H, Jeffers M, Bellacosa A, Mitsuuchi Y, Woude GFV, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proceedings of the National Academy of Sciences. 2001;98(1):247-52.
  27. Hui AY, Meens JA, Schick C, Organ SL, Qiao H, Tremblay EA, et al. Src and FAK mediate cell–matrix adhesion‐dependent activation of met during transformation of breast epithelial cells. Journal of cellular biochemistry. 2009;107(6):1168-81.
  28. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. Journal of Biological Chemistry. 1998;273(50):33714-21.
  29. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911-2.
  30. Maharati A, Moghbeli M. Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-beta, and MAPK signaling pathways during breast tumor progression. Journal of translational medicine. 2023;21(1):556.
  31. Stella MC, Trusolino L, Pennacchietti S, Comoglio PM. Negative feedback regulation of Met-dependent invasive growth by Notch. Molecular and cellular biology. 2005;25(10):3982-96.
  32. Lee C-C, Putnam AJ, Miranti CK, Gustafson M, Wang L-M, Woude GFV, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene. 2004;23(30):5193-202.
  33. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. The EMBO Journal. 1997;16(10):2634-45.
  34. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene. 2002;21(7):1000-8.
  35. Navaei ZN, Khalili-Tanha G, Zangouei AS, Abbaszadegan MR, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. Oncology research. 2021;29(4):235-50.
  36. Maharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell communication and signaling : CCS. 2023;21(1):201.
  37. Boccaccio C, Andò M, Tamagnone L, Bardelli A, Michieli P, Battistini C, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391(6664):285-8.
  38. Zhang Y-W, Wang L-M, Jove R, Vande WG. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002;21(2):217-26.
  39. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nature reviews Molecular cell biology. 2010;11(12):834-48.
  40. Liu Y, Chattopadhyay N, Qin S, Szekeres C, Vasylyeva T, Mahoney ZX, et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development. 2009;136(5):843-53.
  41. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nature reviews Molecular cell biology. 2003;4(1):33-45.
  42. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Molecular biology of the cell. 2007;18(1):76-83.
  43. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature cell biology. 2002;4(9):720-4.
  44. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene. 2004;23(30):5131-7.
  45. Capparuccia L, Tamagnone L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment–two sides of a coin. Journal of cell science. 2009;122(11):1723-36.
  46. Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, et al. Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Developmental cell. 2014;29(4):421-36.
  47. Bachleitner-Hofmann T, Sun MY, Chen C-T, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular cancer therapeutics. 2008;7(11):3499-508.
  48. Follenzi A, Bakovic S, Gual P, Stella M, Longati P, Comoglio P. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000;19(27):3041-9.
  49. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Therapeutic advances in medical oncology. 2011;3(1 suppl):S7-S19.
  50. Sangwan V, Paliouras GN, Cheng A, Dubé N, Tremblay ML, Park M. Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. Journal of Biological Chemistry. 2006;281(1):221-8.
  51. Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbé S, et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Molecular and cellular biology. 2005;25(21):9632-45.
  52. Joffre C, Barrow R, Ménard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nature cell biology. 2011;13(7):827-37.
  53. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory investigation. 2009;89(3):301-14.
  54. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. science. 2007;316(5827):1039-43.
  55. Johnson M, Koukoulis G, Kochhar K, Kubo C, Nakamura T, Iyer A. Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection. Cancer letters. 1995;96(1):37-48.
  56. Kochhar KS, Johnson ME, Volpert O, Iyer AP. Evidence for autocrine basis of transformation in NIH-3T3 cells transfected with met/HGF receptor gene. Growth Factors. 1995;12(4):303-13.
  57. Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M. Role of tyrosine kinases in bladder cancer progression: an overview. Cell communication and signaling : CCS. 2020;18(1):127.
  58. Chen C-T, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Molecular cancer therapeutics. 2012;11(3):660-9.
  59. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. Journal of Biological Chemistry. 2011;286(23):20666-76.
  60. Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med. 2017;3(3):148-53.
  61. Agwa ES, Ma PC. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib. Cancer Manag Res. 2014;6:397-404.
  62. Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016;17(12):1661-71.
  63. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences. 2013;110(32):E2987-E96.
  64. Bagai R, Ma PC. Combined treatment with MET inhibitors and other therapies in lung cancer. Transl Lung Cancer Res. 2012;1(3):214-8.
  65. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients. Journal of Clinical Oncology. 2009;27(10):1667-74.
  66. Petrini I. Biology of MET: a double life between normal tissue repair and tumor progression. Annals of translational medicine. 2015;3(6).
Medical Journal of Mashhad university of Medical Sciences
Volume 68, Issue 6
January and February 2026
Pages 1801-1814

Files

Share

How to cite

Statistics